By offering the databases the partners believe they can support quantitative drug development and provide clients with “valuable insights” into research and marketing programmes.
The databases are designed to assist drug development teams conduct comparative efficacy and safety analysis, link biomarkers to clinical outcomes, predict trial results and develop differentiation strategies.
Sreeni Devidas, vice president of business development at GVK, explained that “the alliance with QS is a major step to create infrastructure that supports the now mandated model of quantitative drug development”.
By providing this infrastructure Devidas believes the partners can maximise the usefulness of pharmacokinetic/pharmacodynamic modeling and simulation (M&S) and increase its value in the drug development process.
Developing databases
QS already has databases covering five indications, rheumatoid arthritis and psoriasis, chronic HCV, neuropathic pain, osteoporosis and major depression, and GVK will distribute these globally.
By capturing summary level data for the clinical safety and efficacy outcomes from publicly available data sources the partners intend to add to this portfolio with databases covering dyslipidemia, schizophrenia and Alzheimer’s.
The partners will also support the databases by providing customisation and consulting services to clients. By doing so they believe clients will have maximum flexibility and benefits.
QS claims there has been a “significant increase in demand” for meta-analyses involving publically available data. Japp Mandema, founder and CEO of QS added that its “customers will benefit greatly from the integrated products and services this partnership provides”.